CD38 and plasma cell myeloma: Studies analyzing MM cells from RRMM patients suggest that prolonged anti-CD38 mAb exposure during post-ASCT maintenance may reduce CD38 expression on myeloma cells, limiting the efficacy of subsequent anti-CD38 therapies.60